Safety of probiotics that contain lactobacilli or bifidobacteria.

S P Borriello, W P Hammes, W Holzapfel, P Marteau, J Schrezenmeir, M Vaara, V Valtonen

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;36(6):775-80

PMID: 12627362

Abstract

Lactobacilli and bifidobacteria are extremely rare causes of infection in humans, as are probiotics based on these organisms. This lack of pathogenicity extends across all age groups and to immunocompromised individuals. Strains used for new probiotics should be chosen from the commensal flora of humans and should not carry intrinsic resistance to antibiotics that would prevent treatment of a rare probiotic infection. Vigilance regarding the detection of possible rare cases of infection due to probiotics should be maintained, and isolates should be sent to reference centers for molecular characterization and confirmation.

Address: Central Public Health Laboratory, London, United Kingdom. [email protected]
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.